{"transactions":[{"id":714048,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T20:05:04.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":650.15,"value":130030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price."}],"balance_after":17303,"source":{"system":"sec-edgar","filing":"0001187443-26-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000010/edgardoc.xml","form_type":"4"}},{"id":794599,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":714.13,"value":1428.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17503,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794598,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":712.09,"value":712.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17505,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794597,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5,"price":711.49,"value":3557.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17506,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794596,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":710.87,"value":1421.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17511,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794595,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":6,"price":709.45,"value":4256.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17513,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794594,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":707.4,"value":2829.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17519,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794593,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":7,"price":706.74,"value":4947.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17523,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794592,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":14,"price":705.56,"value":9877.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17530,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794591,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":15,"price":704.28,"value":10564.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17544,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794590,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":24,"price":703.46,"value":16883.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17559,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794589,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":15,"price":702.46,"value":10536.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17583,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794588,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5,"price":701.76,"value":3508.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17598,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":817910,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":40,"price":779.71,"value":31188.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 40 shares of Company stock on April 1, 2026 at prices ranging from $779.65 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817909,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":778.24,"value":3112.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2026 at prices ranging from $778.02 to $778.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17643,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817908,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":777.42,"value":6996.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2026 at prices ranging from $777.03 to $777.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17647,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817907,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":13,"price":776.62,"value":10096.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2026 at prices ranging from $776.11 to $776.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17656,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817906,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":14,"price":775.58,"value":10858.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2026 at prices ranging from $775.04 to $775.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17669,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817905,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":8,"price":774.58,"value":6196.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $774.05 to $774.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17683,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817904,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":8,"price":773.59,"value":6188.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $773.27 to $773.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17691,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817903,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":772.76,"value":2318.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2026 at prices ranging from $772.62 to $772.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17699,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817902,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":771.32,"value":771.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17702,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":871319,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":20,"price":789.28,"value":15785.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17703,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871318,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":20,"price":788.96,"value":15779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17723,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871317,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":787.34,"value":1574.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17743,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871316,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":7,"price":786.61,"value":5506.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17745,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871315,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":11,"price":785.48,"value":8640.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17752,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871314,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":9,"price":784.48,"value":7060.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17763,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871313,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":10,"price":783.62,"value":7836.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17772,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871312,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":782.62,"value":1565.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17782,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871311,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":781.21,"value":1562.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17784,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871310,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3,"price":780.69,"value":2342.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17786,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871309,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5,"price":779.69,"value":3898.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17789,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871308,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":778.3,"value":1556.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17794,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871307,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":7,"price":777.46,"value":5442.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17796,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":910729,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":787.82,"value":787.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910728,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":2,"price":786.29,"value":1572.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17804,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910727,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":785.71,"value":785.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17806,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910726,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":784.59,"value":784.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17807,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910725,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":3,"price":783.34,"value":2350.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17808,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910724,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":782.53,"value":782.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17811,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910723,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":5,"price":781.48,"value":3907.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17812,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910722,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":780.09,"value":780.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17817,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910721,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":5,"price":779.41,"value":3897.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17818,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910720,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":12,"price":778.53,"value":9342.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17823,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910719,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":57,"price":777.56,"value":44320.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17835,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910718,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":10,"price":776.59,"value":7765.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17892,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910717,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":775.63,"value":775.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17902,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":948751,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:12:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001187443-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000002/edgardoc.xml","form_type":"4"}},{"id":948750,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:12:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":17903,"source":{"system":"sec-edgar","filing":"0001187443-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000002/edgardoc.xml","form_type":"4"}},{"id":1312115,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-01-06T21:08:27.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1958,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":1958},"source":{"system":"sec-edgar","filing":"0001968202-25-000007","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000007/edgardoc.xml","form_type":"4"}},{"id":1312114,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T21:08:27.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":17748,"source":{"system":"sec-edgar","filing":"0001968202-25-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000007/edgardoc.xml","form_type":"4"}},{"id":1393032,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":1059.28,"value":2118.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17582,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393031,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":1057.38,"value":2114.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on October 1, 2024 at prices ranging from $1,057.28 to $1,057.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17584,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393030,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1056.68,"value":3170.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,056.55 to $1,056.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17586,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393029,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1054.9,"value":3164.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,054.76 to $1,054.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17589,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393028,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1053.45,"value":4213.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on October 1, 2024 at prices ranging from $1,053.06 to $1,053.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17592,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393027,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1052.44,"value":4209.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on October 1, 2024 at prices ranging from $1,052.37 to $1,052.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17596,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393026,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":1051.51,"value":9463.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,051.10 to $1,051.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17600,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393025,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":6,"price":1050.6,"value":6303.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 6 shares of Company stock on October 1, 2024 at prices ranging from $1,050.27 to $1,050.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17609,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393024,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":1049.68,"value":9447.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,049.18 to $1,049.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17615,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393023,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":12,"price":1048.54,"value":12582.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 12 shares of Company stock on October 1, 2024 at prices ranging from $1,048.00 to $1,048.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17624,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393022,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":12,"price":1047.44,"value":12569.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 12 shares of Company stock on October 1, 2024 at prices ranging from $1,047.09 to $1,047.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17636,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393021,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":1046.53,"value":9418.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,046.14 to $1,046.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17648,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393020,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":7,"price":1045.27,"value":7316.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on October 1, 2024 at prices ranging from $1,045.00 to $1,045.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17657,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393019,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":1044.62,"value":9401.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,044.14 to $1,044.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17664,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393018,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":5,"price":1043.39,"value":5216.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on October 1, 2024 at prices ranging from $1,043.12 to $1,043.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17673,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393017,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1042.31,"value":1042.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17678,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1393016,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:02:21.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1041.35,"value":3124.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,041.10 to $1,041.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price."}],"balance_after":17679,"source":{"system":"sec-edgar","filing":"0001968202-24-000130","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000130/edgardoc.xml","form_type":"4"}},{"id":1414687,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1191.02,"value":4764.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17682,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414686,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1190,"value":1190.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17686,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414685,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":5,"price":1189.13,"value":5945.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on September 3, 2024 at prices ranging from $1,189.04 to $1,189.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17687,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414684,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1188.55,"value":4754.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17692,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414683,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1187.95,"value":3563.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on September 3, 2024 at prices ranging from $1,187.86 to $1,187.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17696,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414682,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":5,"price":1186.19,"value":5930.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on September 3, 2024 at prices ranging from $1,186.12 to $1,186.47. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17699,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414681,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1185.77,"value":4743.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17704,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414680,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1184.26,"value":1184.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17708,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414679,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":8,"price":1183.47,"value":9467.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,183.39 to $1,183.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17709,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414678,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":8,"price":1179.62,"value":9436.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,179.52 to $1,179.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17717,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414677,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1178.69,"value":4714.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17725,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414676,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1177.73,"value":4710.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17729,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414675,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1176.82,"value":4707.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17733,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414674,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":8,"price":1175.66,"value":9405.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,175.35 to $1,175.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17737,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414673,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":8,"price":1174.32,"value":9394.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,174.14 to $1,174.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17745,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414672,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":16,"price":1172.75,"value":18764.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 16 shares of Company stock on September 3, 2024 at prices ranging from $1,172.66 to $1,172.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price."}],"balance_after":17753,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414671,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1170.4,"value":4681.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17769,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414670,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1168.99,"value":4675.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17773,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414669,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1167.27,"value":1167.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17777,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1414668,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T20:01:10.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":4,"price":1166.52,"value":4666.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17778,"source":{"system":"sec-edgar","filing":"0001968202-24-000124","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000124/edgardoc.xml","form_type":"4"}},{"id":1441598,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:37.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1100.03,"value":1100.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Form two of two"}],"balance_after":17782,"source":{"system":"sec-edgar","filing":"0001968202-24-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000111/edgardoc.xml","form_type":"4"}},{"id":1441588,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1099.65,"value":3298.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,099.49 to $1,099.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F19","text":"Form one of two"}],"balance_after":17783,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441587,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1098,"value":1098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17786,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441586,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1097.69,"value":3293.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,097.25 to $1,097.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17787,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441585,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1096.19,"value":3288.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,096.00 to $1,096.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17790,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441584,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":1095.35,"value":3286.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,095.00 to $1,095.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17793,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441583,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":1094.02,"value":1094.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."}],"balance_after":17796,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441582,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":7,"price":1093.39,"value":7653.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on August 1, 2024 at prices ranging from $1,093.00 to $1,093.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17797,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441581,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":7,"price":1092.61,"value":7648.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on August 1, 2024 at prices ranging from $1,092.27 to $1,092.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17804,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441580,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":13,"price":1091.47,"value":14189.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 13 shares of Company stock on August 1, 2024 at prices ranging from $1,091.00 to $1,091.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17811,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}},{"id":1441579,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:01:22.000Z","date":"2024-08-01","kind":"sale","planned":true,"acquired":false,"shares":11,"price":1090.3,"value":11993.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 11 shares of Company stock on August 1, 2024 at prices ranging from $1,090.00 to $1,090.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price."}],"balance_after":17824,"source":{"system":"sec-edgar","filing":"0001968202-24-000110","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000110/edgardoc.xml","form_type":"4"}}],"next_cursor":"2024-08-05T20:01:22.000000Z,1441579"}